1. Presented by Terance Woodworth, M.S. at the September 9, 2003 meeting of the Anesthetic and Life Support Drugs Advisory Committee

2. Estimates of U.S. Consumption Morphine (sale) (Kg) ARCOS (sales at the retail level) Year-End Reports (distributions by dosage form manufacturers) IMS Health, IMS National Sales Perspectives™ Extracted August 2003 Aggregate Production Quotas

3. Estimates of U.S. Consumption Hydrocodone (sale) (Kg) ARCOS (sales at the retail level) Year-End Reports (distributions by dosage form manufacturers) IMS Health, IMS National Sales Perspectives™ Extracted August 2003 Aggregate Production Quotas

4. Estimates of U.S. Consumption Oxycodone (sale) (Kg) ARCOS (sales at the retail level) Year-End Reports (distributions by dosage form manufacturers) IMS Health, IMS National Sales Perspectives™ Extracted August 2003 ( total kg dispensed) Aggregate Production Quotas

5. Consequences of Increased Availability Morphine Drug Abuse Warning Network IMS Health, National Prescription Audit Plus™ (DAWN Emergency Department Mentions) 1500 1200 900 600 300 0 Total Prescriptions Dispensed (per 100,000 pop.) DAWN Mentions per 100,000 scripts

6. Consequences of Increased Availability Hydrocodone (DAWN Emergency Department Mentions) Drug Abuse Warning Network I MS Health, National Prescription Audit Plus™ 40,000 32,000 24,000 16,000 8,000 0 Total Prescriptions Dispensed (per 100,000 pop.) DAWN Mentions per 100,000 scripts

7. Consequences of Increased Availability Oxycodone (DAWN Emergency Department Mentions) 15,000 12,000 9,000 6,000 3,000 0 Total Prescriptions Dispensed (per 100,000 pop.) Drug Abuse Warning Network IMS Health, National Prescription Audit Plus™ DAWN Mentions per 100,000 scripts

8. Morphine Hydrocodone Oxycodone Consequences of Increased Availability DAWN Mentions per 100,000 scripts Linear Regression Trend line Attachment G

9. State and Local Seizures of Opioids Source: National Forensic Laboratory Information System (NFLIS) 2000 2001 2002 2003 * * As of 8/27/03 Attachment H

10. Promotional Expenditures vs Dollar Sales IMS IPS and NSP Audits* $0 $200,000 $400,000 $600,000 $800,000 $1,000,000 $1,200,000 $1,400,000 $1,600,000 $1,800,000 Actiq Avinza Duragesic Kadian MSContin OxyContin Dollars in Thousands 2002 Total Promotional Dollars 2002 Total Dollars Sales NSP *IMS Health, IMS National Sales Perspectives™, Extracted August 2003 IMS Health, Integrated Promotional Services Audit™, Extracted August 2003